The GZFD Study is evaluating the safety and efficacy of an investigational medicine for adults who have been unable to control their blood sugar levels with semaglutide or tirzepatide.
You may be able to participate in the GZFD Study if you:
· Are aged 18 to 75
· Have type 2 diabetes
· Have been on a stable dose of semaglutide or tirzepatide during the 90 days prior to beginning the study
· Have a BMI* of 27 kg/m2 or greater
If you decide to take part in the GZFD Study, you will be randomly assigned to 1 of 4 groups. Three of these groups will take the investigational medicine. The remaining group will take a placebo, which is a substance that looks like the investigational medicine but contains no active ingredients. Each of the 3 groups taking the investigational medicine will be assigned a different dose.
You will take your assigned study medicine (either the investigational medicine or the placebo) as a subcutaneous injection (under the skin) once a week for 24 weeks. You will continue to take semaglutide or tirzepatide throughout the study, which will be provided as part of study participation. The study will last up to about 10 months (40 weeks), including screening and follow-up, and you will have 11 in-person visits with doctors and researchers at the study center and 1 telehealth visit.
This will be discussed with you by the study team
Participation in clinical trials provides access to innovative and potentially life-saving treatments. It also contributes to medical research, benefiting both current and future healthcare outcomes. It provides cutting-edge medical care under professional supervision and empowers individuals to contribute to the well-being of society. However, participants should carefully weigh up the risks and benefits and seek advice from their doctor before taking part in a trial.
